Understanding asthma phenotypes, endotypes, and mechanisms of disease.
Kuruvilla ME, et al. Clin Rev Allergy Immunol. 2019;56(2): 219-233.-233.
New targeted therapies for uncontrolled asthma.
Corren J. J Allergy Clin Immunol Pract. 2019;7(5):1394-1403
Oral corticosteroid exposure and adverse effects in asthmatic patients.
Sullivan PW, et al. J Allergy Clin Immunol. 2018;141(1):110-116.e7.
T2-“low” asthma: overview and management strategies.
Fitzpatrick AM, et al. J Allergy Clin Immunol Pract. 2020;8(2):452-463.
Treatment options in type-2 low asthma.
Hinks TSW, et al. Eur Respir J. 2021;57(1):2000528.
Tezepelumab in Adults with Uncontrolled Asthma.
Corren J, et al. N Engl J Med. 2017;377(10):936-946.
Efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma: results from the phase 3 NAVIGATOR study.
Menzies-Gow A, et al. J Allergy Clin Immunol. 2021;147(2):AB249.
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial.
Kelsen SG, et al. J Allergy Clin Immunol. 2021;S0091-6749(21)00609-6.
Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma.
Busse WW, et al. Am J Respir Crit Care Med. 2013;188(11):1294-1302.
Clinical Practice Guidelines
Global Strategy for Asthma Management and Prevention.
Global Initiative for Asthma, 2021.
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline.
Holguin F, et al. Eur Respir J. 2020;55(1):1900588.
Clinical Practice Tools
Centers for Disease Control and Prevention (CDC) Asthma Action Plans
These tools for asthma control were created following the evidence-based guidance published by the National Institutes of Health.
Asthma Control Test (ACT)
This 5-question test evaluates asthma control over the past 4 weeks on a 5-point Likert scale. A score of <20 on the ACT suggests asthma that is uncontrolled.
Nathan RA, et al. J Allergy Clin Immunol. 2004;113(1):59-65.
Asthma Control Questionnaire (ACQ)
This 7-question assessment tool measures asthma control over the past 7 days. Six questions are self-administered by the patient, and 1 question requires a clinician’s input. Scores range from 1 (totally controlled) to 6 (severely uncontrolled).
Juniper EF, et al. Eur Respir J. 1999;14(4):902-907.
Asthma Therapy Assessment Questionnaire (ATAQ)
This 4-question test assesses asthma control over the past 4 weeks. Each question has a possible score of 0 or 1; if the sum of the 4 question scores is >1, the patient’s asthma may be uncontrolled.
Vollmer WM, et al. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1647-1652.
Shared Decision-Making Tool
The CHEST Foundation, Allergy and Asthma Network, and American College of Allergy, Asthma & Immunology (ACAAI) have developed a shared decision-making tool for adults with severe asthma so that they may work collaboratively with clinicians to improve self-management skills, choose the best treatment plan, and increase adherence.
Patient Advocacy Organizations and Resources
Asthma and Allergy Foundation of America (AAFA)
AAFA is dedicated to improving the quality of life for people with asthma and allergic diseases through education, advocacy, and research.
American College of Allergy, Asthma & Immunology (ACAAI)
The ACAAI fosters a culture of collaboration and congeniality in which members work toward the common goals of patient care, education, advocacy, and research.
American Lung Association
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research.
American Thoracic Society (ATS)
The mission of the ATS is to improve health worldwide by advancing research, clinical care, and public health in respiratory disease, critical illness, and sleep disorders.
The CHEST Foundation creates trusted patient education resources and disease awareness campaigns that empower patients to engage in better managing their health.